Enzymatica's Chairman to BioStock: "Our new research data makes 2024 an exciting year”
In 2023, Enzymatica presented important research results for ColdZyme and strengthened the marketing of the product. However, the sales growth has been lower than expected during the year, especially outside the company’s own markets. Despite this, the company remains committed to its long-term financial targets and looks ahead to what is to come in 2024. The company's Chairman of the Board, Bengt Baron, tells us more in an interview.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se